A health-research organization called ATI Advisory has released what I find to be a fascinating study about the research and development (R&D) spending on the list of 10 expensive drugs that Medicare selected for the price-negotiation process authorized by the Inflation Reduction Act (IRA). You can find details about that announcement in an earlier post.
Keep reading with a 7-day free trial
Subscribe to Aging in America to keep reading this post and get 7 days of free access to the full post archives.